Skip to main content
SpringerLink
Log in

Recent Advances in Drug Development and Regulatory Science in China

  • Global Perspectives: Original Article
  • Published:
Therapeutic Innovation & Regulatory Science Aims and scope Submit manuscript

Abstract

As the second largest pharmaceutical market with a great potential for future growth, China has drawn much attention from the global pharmaceutical community. With an increasing government investment in biomedical research, the domestic biopharmaceutical (biotechnological) companies in China are turning their attention to the development of innovative medicines and targeting the global market. To introduce innovative products to Chinese patients sooner, to improve the efficiency of its review and approval processes, and to harmonize its regulatory science with international standards, the China Food and Drug Administration (CFDA) has initiated a series of major changes to its policies and regulations. This paper presents a snapshot of China’s pharmaceutical market, and research and development status, and introduces technical guidelines pertaining to clinical trials and new drug applications. The recent wave of ground-breaking reforms in CFDA’s regulatory science is discussed. Examples of clinical trials and new drug applications are provided throughout the discussion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. International Trade Administration: 2016 top markets report pharmaceuticals country case study—china. Technical report, 2017, U.S. Department of Commerce.

  2. GlobalData. Country focus: healthcare, regulatory and reimbursement landscape. US. Technical Report, 2016, GlobalData UK Ltd.

  3. IMS: IMS Market Prognosis 2016-2020 Asia/Australia China. Technical report, 2016, IMS Health, London.

  4. United Nations. World Population Ageing 2015. Department of Economics and Social Affairs, 2015, United Nations, New York.

    Google Scholar 

  5. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. Cancer J Clin. 2016;66:115–132.

    Article  Google Scholar 

  6. Wu L. Rate of diabetes in China explosive. World Health Organization news release, 2016. http://www.wpro.who.int/china/mediacentre/releases/2016/20160406/en/.

  7. Beier D, Baeder G. China set to accelerate life science innovation. Forbes. https://www.forbes.com/sites/realspin/2017/07/06/china-set-to-accelerate-life-science-innovation/#354713f1e73b. Published July 6, 2017.

  8. Normile D. Medical centers spearhead China’s pharma push. Science. 2017;358:709.

    Article  CAS  Google Scholar 

  9. Ni J, Zhao J, Ung COL, Hu Y, Hu H, Wang Y. Obstacles and opportunities in Chinese pharmaceutical innovation. Global Health. 2017;13:21.

    Article  Google Scholar 

  10. Bradshaw J. More wealth, less health: the changes fueling Chinas drug industry boom. Telegraph Business. http://www.telegraph.co.uk/business/2017/03/04/wealth-less-health-changes-fuelling-chinas-drug-industry-boom/. Published March 4, 2017.

  11. A better pill from China: Chinese pharma firms target the global market. The Economist. March 16, 2017.

  12. Zhao N, Yao C, Chen J. On the amendments of China’s provisions for drug registration. Drug Inform J. 2008;42:467–475.

    Article  Google Scholar 

  13. International Conference on Harmonisation. Statistical principles for clinical trials. London: ICH, 1998.

    Google Scholar 

  14. US Food and Drug Administration. Guideline for the Format and Content of the Clinical and Statistical Sections of an Application. Rockville, MD: FDA, 1988.

    Google Scholar 

  15. Chen F, Chen Q, Chen J, Hsu J. Current statistical requirements for pharmaceutical clinical trials in China. Drug Inform J. 2008;42:321–330.

    Article  Google Scholar 

  16. China Food and Drug Administration. Biostatistical guideline for drug clinical trials. 2016 (http://www.cde.org.cn/zdyz.do?method=largePage&id=272).

  17. China Food and Drug Administration. Guideline for international multi-center clinical trials. January 2015 (http://www.sda.gov.cn/WS01/CL0087/114002.html).

  18. ICH. General principles for planning and design of multi-regional clinical trials. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E17/E17EWG_Step4_2017_1116.pdf. Published November 2017.

  19. MHLW. Basic principles on global clinical trials. Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare, Tokyo, Japan. 2012.

    Google Scholar 

  20. MHLW. Basic principles on global clinical trials. Notification No. 0928010, Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare, Tokyo, Japan. 2007.

    Google Scholar 

  21. China Food and Drug Administration. Phase report of drug clinical trial data verification. China Food Drug Newsletter. 2017;8:6–7.

    Google Scholar 

  22. China Food and Drug Administration. Guideline for data management and statistical analysis plans and reports in drug clinical trials. China Food and Drug Administration. http://www.cde.org.cn/zdyz.do?method=largePage&id=270. Published July 2016.

  23. Sheng Laiyun, ed. China Statistical Yearbook. Hong Kong: China Statistics Press; 2016.

    Google Scholar 

  24. Zhang YL, Yuan JQ, Wang KF, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7:7898578993.

    Google Scholar 

  25. WHO. The WHO cross-national study of health behavior in school-aged children from 35 countries: findings from 2001–2002. J Sch Health. 2004;74:204–206.

    Article  Google Scholar 

  26. Wang B, Davidson A. An overview of major reforms in China’s regulatory environment. Regul Rapport. 2017;14:5–9.

    Google Scholar 

  27. Gregory P. Regulatory changes position China as a global clinical trial destination. Appl Clin Trials. September 11, 2017.

  28. Big pharma gets boost as China speeds up new drug approvals. Bloomberg News. https://www.bloomberg.com/news/articles/2017-10-09/china-launches-overhaul-of-drug-approval-in-win-for-big-pharma. Published October 9, 2017.

  29. Cyranoski D. China announces plans to fast-track drug approval. Nature News, October 26, 2017.

  30. Balzano J, Chen S, Zhao A. Chinese Government initiates significant drug and device regulatory reforms. Covington & Burling LLP. November 6, 2017.

  31. McCallister E. Opening the gates in China. Biocentury. December 1, 2017.

  32. China Food and Drug Administration. CFDA issued the 2016 drug review annual report. China Food Drug Newsletter. 2017;4:4–6.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Merck Research Laboratories, BARDS Methodology Research, UG1D016, Upper Gwynedd, PA, 19454, USA

    Jie Chen PhD

  2. Department of Biostatistics, School of Public Health, Fudan University, Shanghai, China

    Naiqing Zhao MS (Professor of Statistics)

Authors
  1. Jie Chen PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naiqing Zhao MS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jie Chen PhD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, J., Zhao, N. Recent Advances in Drug Development and Regulatory Science in China. Ther Innov Regul Sci 52, 739–750 (2018). https://doi.org/10.1177/2168479018764661

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/2168479018764661

Keywords

Search

Navigation